Prognostic Value of Baseline Metabolic Tumor Volume on [18F]FDG PET/CT in Metastatic Breast Cancer Treated With CDK4/6 Inhibitors. (PubMed, Clin Breast Cancer) - Oct 16, 2026 - "Baseline TMTV is an independent prognostic factor for both PFS and OS in patients with HR+/HER2- MBC treated with CDK4/6 inhibitors."
Journal • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2
|
|
Berna Okudan; Elif Reyhan Aslan; Osman Inan; Oznur Bal; Refia Yukselturk; Seyma Erdogan
|